PHARMACEUTICAL COMPOSITION Russian patent published in 2018 - IPC A61K38/28 A61P3/10 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to the treatment of conditions like diabetes mellitus and hyperglycaemia, in particular of insulin-dependent diabetes mellitus. Method for treating diabetes mellitus comprises administering once a day to a subject at the largest meal of the day for said subject a pharmaceutically acceptable combination comprising LysB29(Nε-Hexadecanediol-γ-Glu)des(B30) human insulin and Asp^B28 human insulin; wherein said combination is administered in an amount to achieve a beneficial glycaemic control in said subject as determined by the levels of HbA_1c in said subject; wherein said beneficial glycaemic control by said combination is superior to any glycaemic control achieved by an equivalent dose of IGlar in said subject as determined by the levels of HbA_1c in said subject after administration of IGlar, wherein said beneficial glycaemic control by said combination comprises decreasing the levels of Hb_A1c in the subject to about 7 or less; wherein the decrease in the levels of HbA_1c in the subject is achieved at about 26 weeks or less.

EFFECT: invention allows achieving beneficial glycaemic control as it provides flexibility of administration of the combination to the subject.

7 cl, 2 dwg, 34 tbl, 5 ex